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Gene symbols, names and description of genes analyzed by qPCR ______________________________________________________________________________
HGNC

Common Brief description Symbol Symbol(s)
ALOX15B 15-LOX-2
Arachidonate 15-lipoxygenase, type B, converts arachidonic acid to 15S-hydroperoxyeicosatetraenoic acid. CD163
M130, MM130 Member of the scavenger receptor cysteine-rich superfamily. Found on monocytes and macrophage, CD163 is an acute phase factor involved in the clearance of haemoglobin/haptoglobin. May help protect from free-haemoglobine-mediated oxidated damage. CD163 may be an innate sensor for bacteria. CEBPD C/EBPδ CCAAT/enhancer binding protein δ is a bZIP transcription factor that is involved in the regulation of immune and inflammatory responses. CDKN1C p57KIP2
Cyclin-dependent kinase inhibitor 1C inhibits G1 cyclin/Cdk complexes to negatively regulate cell cycle. Reported to interact with and inhibit JNK MAPKs (10, 11). CNR1 CB1, CNR Cannabinoid receptor 1 is a GPCR that inhibits adenylyl cyclase activity. CXCR4 LAP3, LCR1 Chemokine (C-X-C motif) receptor 4 is a GPCR receptor for stromal cell-derived factor 1 (SDF1) (CXCL12) DUSP1 MKP1
Dual-specificity phosphatase 1 / mitogen-activated protein kinase phosphastas 1 is upregulated by inflammatory pathways and by glucocorticoids to dephosphorylate and, thereby inactivate, MAPK family members including ERK, p38 MAPK and JNK (12, 13). FAM150B PRO1097 Function unknown. FKBP5 FKBP51 FK506 binding protein 5 is an immunophilin that interacts with the cytoplasmic Hsp90/nuclear hormone receptor complex to negatively regulate GR function (14-16). IGF1 MGF Insulin-like growth factor 1 (somatomedin C) is similar to insulin in function and mediates growth and development. KLF9 BTEB Krupple-like factor 9 is a GC box transcription factor. LIFR CD118 Leukemia inhibitor factor receptor alpha is a type I cytokine receptor that binds to gp130 to form a functional receptor complex. Mediates differentiation, proliferation and survival. NFKBIA IBα NFκB inhibitor alpha is an endogenous cytoplasmic inhibitor of the inflammatory transcription factor NF-κB.
PDK4
Pyruvate dehydrogenase kinase, isozyme 4. Involved in the regulation of glucose metabolism. PER1 PER, RIGUI Member of the Period family of genes. A transcription factor that is regulated in a circadian manner. RGS1 1R20, BL34 Regulator of G-protein signaling (RGS) 1 is a GTPase-activating protein (GAP) for the Gα subunit of heterotrimeric G proteins. It is a Gi/oα-selective RGS that plays roles in regulating responses to chemokines (17, 18). RGS2 RGS2 Regulator or G-protein signaling 2 is a GTPase-activating protein (GAP) for the Gα subunit of heterotrimeric G proteins. RSG2 is selective for Gqα and attenuates signaling by bronchonstrictor stimuli, including histamine, methacholine and U46619 (19, 20) .
SLC45A1 DNB5
Solute carrier 45A1 is an integral membrane symporter categorized as a protonassociated sugar transporter that may show glucose transporter activity.
TFCP2L1 LBP9
Transcription factor CP2-like 1. TLR2 TIL4, CD82 Toll-like receptor 2 plays a role in pathogen recognition and activation of innate immunity. TSC22D3 GILZ TSC22D3 is a leucine zipper protein believed to be a transcriptional regulator that negatively regulates inflammatory signaling to reduce NF-B-and AP-1-dependent transcription (21, 22) (23, 24) . ZBTB16 PLZF Zinc finger and BTB domain containing 16 is a transcription factor that interacts with HDACs and may play roles in transcriptional repression. ZFP36 TTP Zinc finger protein 36 / tristetraprolin is a RNA binding protein which regulates the mRNA decay of mRNAs via AUUUA motifs. Expression is up-regulated by inflammatory stimuli, such as IL1B, to provide feedback control (25, 26) . ______________________________________________________________________________ Information was taken from NCBI Gene and supplemented with the indicated references.
SUPPLEMANTAL RNA was prepared from biopsy samples taken 5-6h after placebo (Plac) or budesonide (1600µg) (Bud) inhalation. Total RNA was subjected to expression profiling using Affymetrix PrimeView microarrays. Analysis (n = 11 individuals) was performed with Partek Genomics Suite (Version 6.6) using robust multi-array averaging (RMA FOXO3, HIF3A, KLF9, KLF15, PER1, TFCP2L1  <2/≥1.5  AFF3, ASCL3, CEBPD, FHL5, FOSL2, FOXO1, IKZF1, KLF7, KLF13, PPARGC1A, TCF21, TFEB,  TOX, TOX2  <1.5/≥1.25 ARNTL, ATF5, ATOH8, CAMTA1, CSRNP1, FOXN2, GLIS3, HAND2, IRX3, KLF2, KLF6, LMO2 qPCR data for the indicated genes were taken from Figs 1 -3 and are displayed as fold of placebo. Using the microarray data presented in Fig. 1A of the main manuscript, all probe sets corresponding to each of the indicated genes were identified and the fold induction for the individual probe sets provided. The relationship between qPCR and array data are plotted in Supplemental Fig. 4 . Significance for qPCR and array data is as described in Figures 1 -3 of the main manuscript. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.
SUPPLEMENTAL The 72 probe sets meeting the expression criteria (≥2 fold, FDR 0.05) were analyzed using the DAVID gene ID conversion tool to provide a list of 46 up-regulated genes. Functional annotation clustering was performed in DAVID using a medium stringency. This produced 15 annotation clusters of which the top 12 are shown. GO terms mapping to each cluster are listed along with the total genes within each cluster. GO terms that are significantly associated with the gene list are indicated. * P≤0.05, ** P≤0.01. Abbreviations: Reg = regulation, -ve = negative, +ve = positive. regulation of nitrogen compound metabolic process; GO:0009890~negative regulation of biosynthetic process**; GO:0051173~positive regulation of nitrogen compound metabolic process**; GO:0009891~positive regulation of biosynthetic process*; GO:0000904~cell morphogenesis involved in differentiation; GO:0032989~cellular component morphogenesis; GO:0008283~cell proliferation; GO:0006915~apoptosis; GO:0051249~regulation of lymphocyte activation; GO:0046649~lymphocyte activation; GO:0001568~blood vessel development;GO:0051272~positive regulation of cell motion**; GO:0006350~transcription; GO:0051253~negative regulation of RNA metabolic process; GO:0016310~phosphorylation**; GO:0031399~regulation of protein modification process; GO:0001932~regulation of protein amino acid phosphorylation; GO:0043065~positive regulation of apoptosis; GO:0002694~regulation of leukocyte activation; GO:0030030~cell projection organization; GO:0003006~reproductive developmental process; GO:0032535~regulation of cellular component size 2. GO terms associated with (P≤0.05) Budesonide down-regulated genes (≤0.5 fold, P≤0.05) Transcription: No GO terms Signaling: GO:0007166~cell surface receptor linked signal transduction; GO:0007186~G-protein coupled receptor protein signaling pathway; GO:0032101~regulation of response to external stimulus; GO:0019932~second-messengermediated signaling; GO:0005125~cytokine activity***; GO:0008009~chemokine activity**; GO:0042379 ~chemokine receptor binding**; GO:0048019~receptor antagonist activity; GO:0030547~receptor inhibitor activity; GO:0030545~receptor regulator activity; hsa04060:Cytokine-cytokine receptor interaction**; hsa04062:Chemokine signaling pathway** Metabolism: GO:0030574~collagen catabolic process; GO:0032963~collagen metabolic process; GO:0044259~multicellular organismal macromolecule metabolic process; GO:0044236~multicellular organismal metabolic process; GO:0044243~multicellular organismal catabolic process Proliferation, apoptosis and death: GO:0008284~positive regulation of cell proliferation Defence and immune: GO:0009611~response to wounding***; GO:0006952~defense response***; GO:0006954~ inflammatory response***; GO:0006955~immune response; GO:0002684~positive regulation of immune system process Cell motion, migration: GO:0007155~cell adhesion**; GO:0022610~biological adhesion**; GO:0042330~taxis***; GO:0006935~chemotaxis***; GO:0007626~locomotory behavior**; GO:0016477~cell migration*; GO:0048870~cell motility*; GO:0051674~localization of cell*; GO:0006928~cell motion*; GO:0050900~leukocyte migration**; GO:0016337~cell-cell adhesion; GO:0050901~leukocyte tethering or rolling; GO:0045123~cellular extravasation GO:0007157~heterophilic cell adhesion; GO:0007159~leukocyte adhesion; GO:0030595~leukocyte chemotaxis; GO:0060326~cell chemotaxis Other: GO:0007610~behavior**; GO:0010033~response to organic substance*; GO:0006874~cellular calcium ion homeostasis*; GO:0055074~calcium ion homeostasis*; GO:0048545~response to steroid hormone stimulus*; GO:0006875~cellular metal ion homeostasis*; GO:0055065~metal ion homeostasis*; GO:0030005~cellular di-, trivalent inorganic cation homeostasis; GO:0055066~di-, tri-valent inorganic cation homeostasis; GO:0030003~cellular cation homeostasis; GO:0055080~cation homeostasis; GO:0009725~response to hormone stimulus; GO:0006873 ~cellular ion homeostasis; GO:0055082~cellular chemical homeostasis; GO:0009719~response to endogenous stimulus; GO:0050801~ion homeostasis; GO:0019725~cellular homeostasis; GO:0048878~chemical homeostasis
The 889 probe sets showing ≥1.25 fold induction (P≤0.05) by budesonide (Supplemental Table 3 ) in the microarray analysis depicted in Fig. 2 were analyzed using the DAVID gene identity conversion tool. This produced 588 separate gene identities, which were analyzed using the DAVID functional annotation tool (default settings, medium stringency) and resulted in 647 GO terms containing at least 2 gene symbols each. Of these, 420 were significantly associated (P≤0.05) with the gene list and 235 corresponded to GO terms for biological process (GOTERM_BP_FAT) or KEGG (KEGG_PATHWAY). Selected terms used to generate Fig. 2A are listed above (Supplemental Table 7 , part 1A). Significantly associated terms not used in Fig. 2A are listed (Supplemental Table 7 , part 1B).
Terms showing significant fold enrichment, Benjamini ≤0.05, ≤0.01 & ≤0.001, with budesonide inhalation are indicated (*, **, and *** respectively). An identical analysis was also performed on the 35 probe sets down-regulated ≤0.5 fold (P≤0.05) by inhaled budesonide. The 28 genes thus identified were subjected to functional annotation to give 107 GO terms that were significantly associated with the probe list. Of these 57 correspond to biological process (GOTERM_BP_FAT) or KEGG (KEGG_PATHWAY) or molecular function (GOTERM_MF_FAT) and are listed above (Supplemental Table 7 , part 2). Selected terms are used in Figure 2C . Terms showing significant fold enrichment, Benjamini ≤0.05, ≤0.01 & ≤0.001, with budesonide are indicated (*, **, and *** respectively). -05  APBB1, ARNTL, ATXN7, BMP2, CD86, CITED2, CSRNP1, ERCC6, F2R, FOXO1, FOXO3,  FOXO3B, GLIS3, HAND2, HIPK2, HMGB2, IGF1, IKZF1, INHBA, INSR, KLF13, KLF15,  KLF2, KLF6, KLF7, MAFB, MGEA5, NFIB, NFIC, NFKBIA, NR2E3, PDGFRA, PIAS1,  PPARGC1A, RORA, RUNX2, TBX21, TCF21, TFEB, THRA, TTF1, CELF6, CITED2, CREBRF, CSRNP1, ERCC6, F2R, FOSL2, FOXN2, FOXO1, FOXO3,  FOXO3B, GLIS3, GZF1, HAND2, HIF3A, HIPK2, HMGB2, IGF1, IKZF1, INHBA, INSR,  IRX3, KLF13, KLF15, KLF6, KLF7, KLF9, MAFB, NFATC2IP, NFIA, NFIB, NFIC, NFIL3,  NFKBIA, NR2E3, PBX4, PER1, PIAS1, PPARGC1A, RORA, RPS6KA5, RUNX2, SIK1, SLA2,  SMARCD2, SPEN, TBX21, TCF21, TFCP2L1, TFEB, THRA, TNFSF4, TSC22D3, TTF1,  ZBTB16, ZBTB38, ZFHX3, ZHX3, ZNF157, ZNF234, ZNF275, ZNF320, ZNF331, ZNF540,  ZNF561 , ZNF57, ZNF682, ZNF763, ZNF844 AFF3, APBB1, ARNTL, ASCL3, ATAD2, ATF5, ATOH8, ATRX, ATXN7, BATF, BCL6,  BMP2, CAMTA1, CD86, CDKN1C, CEBPD, CITED2, CREBRF, CRY2, CSRNP1, EID3,  ERCC6, F2R, FAM120B, FOSL2, FOXN2, FOXO1, FOXO3, FOXO3B, GLIS3, GZF1,  HAND2, HIF3A, HIPK2, HMGB2, IGF1, IKZF1, IL16, INHBA, INSR, IRAK3, IRX3, JADE1,  KLF13, KLF15, KLF2, KLF6, KLF7, KLF9, MAFB, NFATC2IP, NFIA, NFIB, NFIC, NFIL3,  NFKBIA, NR2E3, PBX4, PER1, PIAS1, POU2AF1, PPARGC1A, PRR15L, RORA, RPS6KA5,  RUNX2, SCML4, SIK1, SLA2, SMARCD2, SNAPC3, SPEN, TBX21, TCF21, TFCP2L1,  TFEB, TGFBR3, THRA, TLR2, TNFSF4, TOX2, TSC22D3, TSPYL2, TTF1, VGLL3, ZBTB16,  ZBTB20, ZBTB38, ZBTB8A, ZFHX3, ZHX3, ZNF157, ZNF234, ZNF275, ZNF320, ZNF331,  ZNF540, ZNF561, ZNF57, ZNF652, AKAP13, AKAP9, AKT3, BLK, CAMK2B, CCND3, CIT, CSF1R, DAPK1, ERBB4, FGR,  FLT3, HIPK2, INSR, IRAK3, LATS2, MAP3K6, MERTK, MKNK2, NIM1K, NTRK3, PAK3,  PDGFRA, PDK4, PHKA1, PRKCA, PTK2B, ROR1, RPS6KA2, RPS6KA5, SGK1, SIK1,  TAOK1, TGFBR3, TRIO, TXK CIT, CSF1R, DAPK1, DGKG, ENPP1, ERBB4, ERCC6, ETNK2, FGR, FLT3, GIMAP1, GLUL,  HCAR2, HCAR3, HIPK2, HK1, INSR, IRAK3, LATS2, MAP3K6, MERTK, MKNK2, MYO10,  N4BP2, NIM1K, NMUR2, NTRK3, P2RX5, PAK3, PAPSS2, PDGFRA, PDK4, PDXK,  PFKFB2, PRKCA, PRR15L, PTK2B, RAB31, RAB40A, RAB8B, RAPGEF3, RHOB,  RHOBTB3, RHOU, ROR1, RPS6KA2, RPS6KA5, RRAGD, RUNX2, SGK1, SIK1, TAOK1,  TRIO, TXK, UBE2D2, UBE2H, The 889 probe sets showing ≥1.25 fold (P≤0.05) induction by budesonide in the biopsy microarray analysis were analyzed using the DAVID gene ID conversion tool to produce 588 separate identities that were used for functional annotation clustering in DAVID (default settings, medium stringency). This returned 183 clusters of which those with the highest 20 enrichment scores are shown. % = percentage of the gene list with associated probability (P). Fold = fold enrichment with the associated Benjamini score.
SUPPLEMENTAL
SUPPLEMENTAL Human bronchial epithelial cells were either not treated or treated with 0.1 μM budesonide (Bud) prior to harvesting at 6 h. Total RNA was subjected to expression profiling using Affymetrix PrimeView microarrays. Analysis (n = 6 independent donors) was performed with Partek Genomics Suite (Version 6.6). HBE cells were either not treated or treated with 0.1 μM budesonide (Bud) prior to harvesting at 6 h. Total RNA was subjected to expression profiling using Affymetrix PrimeView microarrays. Analysis (n = 6 independent donors) was performed with Partek Genomics Suite (Version 6.6). Resultant fold expression and P values for all probe sets showing ≥2 or ≤0.5 fold (P≤0.05) were analyzed using the DAVID gene ID conversion tool to produce individual gene identities. Using gene ontology (GO) information and functional information from NCBI Gene, gene symbols were categorized into six general groups: 1, Transcriptional control; 2, Membrane receptors; 3, Signaling and regulation of signaling; 4, Metabolic and metabolism; 5, Other function; or 6, Function not assigned and further sub-divided as indicated. Genes subjected to qPCR validation are underlined.
Supplemental Figures
Supplemental Fig. 1 . Study design: overview and procedures conducted at each visit. Following screening, the study participants were each randomized to receive either inhaled placebo followed by inhaled budesonide, or inhaled budesonide followed by inhaled placebo. Each treatment intervention was separated by a 2-3 week washout period. Randomization was performed by research pharmacy personnel, not otherwise associated with the study.
Supplemental Fig. 4 . Comparison of biopsy microarray data with qPCR analysis of budesonide-induced genes. (A) Of the genes analyzed by qPCR in Figs. 1-3 in the main paper, many corresponded to multiple microarray probe sets (Supplemental Table 5 were not treated or treated with budesonide (0.1 μM). RNA was prepared and microarray analysis performed using Affymetrix Primeview arrays. Analysis was performed with Partek Genomics Suite (v6.6) using robust multi-array averaging (RMA) and resultant fold expression and P values used to generate a volcano plot (Supplemental Fig. 2 ). (B) GO analysis of biological process. Budesonideinduced and -repressed probe sets meeting the criteria; i, ≥2 fold, P≤0.05, or ii, ≤0.5 fold, P≤0.05 were analyzed using the DAVID gene ID conversion tool to give: i, 84 up-regulated and ii, 114 down-regulated genes, respectively (Supplemental Table 10 ). Each gene list was analyzed by DAVID functional annotation, which produced gene clusters (≥2 genes/cluster) corresponding to 99 and 194 GO annotation terms respectively. GO terms corresponding to biological process (GOTERM_BP_FAT and KEGG_PATHWAY) were extracted. Selected terms are plotted with the numbers of genes (as a percentage of total) for each term along with the fold enrichment for each term. Abbreviations are as used in Figure 2 of the main manuscript.
